HTG Molecular Diagnostics, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2016-11-17: Form 8-K; Period of report 2016-11-16; Description 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; Details 1.01.
- 2016-11-14: Form 8-K; Period of report 2016-11-14; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2016-08-30: Form 8-K; Period of report 2016-08-25; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders; Details 5.02.
- 2016-08-19: Form 8-K; Period of report 2016-08-15; Description 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; Details 3.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2016-11-17 | 8-K | 2016-11-16 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. 3.02 The information contained under Item 1.01 of this report relating to the issuance and sale of the Company’s common stock pursuant to the Stock Purchase Agreement is incorporated in this Item 3.02 by reference. | htgm-8k_20161115.htm |
| 2016-11-14 | 8-K | 2016-11-14 | 2.02 Results of Operations and Financial Condition | 2.02 On November 14, 2016, HTG Molecular Diagnostics, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2016. | htgm-8k_20161114.htm |
| 2016-08-30 | 8-K | 2016-08-25 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | 5.02 As previously announced in a press release issued on August 29, 2016, on August 25, 2016 the Board of Directors (the “Board”) of HTG Molecular Diagnostics, Inc. (the “Company”), upon recommendation of the Nominating and Governance Committee of the Board (the “Nominating Committee”), appointed Ann F. Hanham, Ph.D. to serve as a Class III director of the Company, with a term expiring at the Company’s annual meeting of stockholders to be held in 2018. 5.07 On August 25, 2016 the Company held its 2016 Annual Meeting of Stockholders (the “Annual Meeting”). | htgm-8k_20160825.htm |
| 2016-08-19 | 8-K | 2016-08-15 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On August 15, 2016, HTG Molecular Diagnostics, Inc. (the “Company”) received notice from the Nasdaq Stock Market LLC (the “Notice”) that the Company’s stockholders’ equity as reported in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2016 does not satisfy the Nasdaq Global Market continued listing requirement set forth in Nasdaq Stock Market Rule 5450(b)(1)(A) (the “Rule”). | d244721d8k.htm |
| 2016-08-09 | 8-K | 2016-08-09 | 2.02 Results of Operations and Financial Condition | 2.02 On August 9, 2016, HTG Molecular Diagnostics, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2016. | htgm-8k_20160809.htm |
| 2016-06-01 | 8-K | 2016-05-26 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Our principal executive officer, principal financial officer and our other named executive officers (which we refer to herein collectively as “executive officers”) are eligible to receive annual performance-based bonuses pursuant to their employment agreements with us. | htgm-8k_20160526.htm |
| 2016-05-12 | 8-K | 2016-05-12 | 2.02 Results of Operations and Financial Condition | 2.02 On May 12, 2016, HTG Molecular Diagnostics, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2016. | htgm-8k_20160512.htm |
| 2016-05-03 | 8-K | 2016-05-02 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On May 2, 2016, the Board of Directors (the “Board”) of HTG Molecular Diagnostics, Inc. (the “Company”), upon recommendation of the Nominating and Governance Committee of the Board (the “Nominating Committee”), appointed Donnie (Don) M. Hardison to serve as a Class II director of the Company with a term expiring at the Company’s annual meeting of stockholders to be held in 2017. | htgm-8k_20160502.htm |
| 2016-03-31 | 8-K | 2016-03-28 | 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 2.03 As previously reported, we entered into a Loan and Security Agreement (as amended, the “Agreement”) with Oxford Finance LLC (“Oxford”), as collateral agent and a lender, and Silicon Valley Bank (“SVB”), as a lender, on August 22, 2014, providing for two separate term loans in an aggregate principal amount of $16.0 million. 3.02 In connection with the Term B Loan, on March 28, 2016 we issued to Oxford a warrant to purchase 45,307 shares of our Common Stock at an exercise price of $2.759 per share. | d113560d8k.htm |
| 2016-03-24 | 8-K | 2016-03-24 | 2.02 Results of Operations and Financial Condition | 2.02 On March 24, 2016, HTG Molecular Diagnostics, Inc. issued a press release announcing its financial results for the quarter and year ended December 31, 2015. | d139936d8k.htm |
| 2016-03-21 | 8-K | 2016-03-16 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d155738d8k.htm |
| 2016-02-10 | 8-K | 2016-02-10 | 7.01 Regulation FD Disclosure | 7.01 • As of December 31, 2015, we had an installed base of 49 HTG Edge and HTG EdgeSeq systems, consisting of 22 systems sold, five covered under reagent rental agreements, three with key opinion leaders and 19 evaluation units. | d137767d8k.htm |
| 2016-01-11 | 8-K | 2016-01-11 | 7.01 Regulation FD Disclosure | 7.01 HTG Molecular Diagnostics, Inc. (the “Company”) intends to provide previously nonpublic information about the Company in its presentation handout to be utilized in various meetings with securities analysts and investors at the 34th Annual J.P. Morgan Healthcare Conference, commencing on January 11, 2016. | d121064d8k.htm |